Abstract: A therapeutic method is provided, employing an antiviral compound of the general formula: ##STR1## wherein Z is H, OR' or N(R).sub.2, where n R' is H, (C.sub.1 -C.sub.4)alkyl, aryl, CHO, (C.sub.1 -C.sub.16)alkanoyl or O.dbd.P (OH).sub.2, Y is CH or N, and X is selected from the group consisting of H, N(R).sub.2, SR, OR' or halogen, wherein R is H, lower(C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically acceptable salts thereof.

Abstract: A method is provided for preparing an antiviral compound of formula (I): ##STR1## wherein Y is CH, Z is H or NH.sub.2, and X is halo, comprising: (a) reacting a compound of formula (II): ##STR2## with triethylorthoformate, and (b) hydrolyzing the product of said reaction in the presence of acid to yield said compound of formula (I).

Abstract: A therapeutic method is provided, employing an antiviral compound of the general formula: ##STR1## wherein Z is H, OR' or N(R).sub.2, wherein R' is H, (C.sub.1 -C.sub.4)alkyl, aryl, CHO, (C.sub.1 -C.sub.16)alkanoyl or O.dbd.P(OH).sub.2, Y is CH or N, and X is selected from the group consisting of H, N(R).sub.2, SR, OR' or halogen, wherein R is H, lower(C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically acceptable salts thereof.

Abstract: A therapeutic method is provided, employing an antiviral compound of the general formula: ##STR1## wherein Z is H, OR' or N(R).sub.2, wherein R' is H, (C.sub.1 -C.sub.4)alkyl, aryl, CHO, (C.sub.1 -C.sub.16)alkanoyl or O.dbd.P(OH).sub.2, Y is CH or N, and X is selected from the group consisting of H, N(R).sub.2, SR, OR' or halogen, wherein R is H, lower(C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically acceptable salts thereof.

Abstract: This invention relates to the new process for preparing the 1R-cis isomer of carbovir, (1R-cis)-amino-1,9-dihydro-9-[4-(hydroxymethyl)-2-cyclopenten-1-yl]-6H-pur in-6-one, an antiviral agent and intermediates of the formula (Vlb) use in that process ##STR1## wherein X is chloro, bromo or iodo and R is (C.sub.1-6) alkyl.

Abstract: A therapeutic method is provided, employing an antiviral compound of the general formula: ##STR1## wherein Z is H, OR' or N(R) .sub.2, wherein R' is H, (C.sub.1 -C.sub.4)alkyl, aryl, CHO, (C.sub.1 -C.sub.16)alkanoyl or O.dbd.P(OH) .sub.2, Y is CH or N, and X is selected from the group consisting of H, N(R) .sub.2, SR, OR' or halogen, wherein R is H, lower (C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically acceptable salts thereof.

Abstract: This invention relates to new process for preparing certain optically active purine substituted cyclopentene derivatives and novel intermediates used in this process. In particular, the invention concerns the synthesis of the 1R-cis isomer of carbovir, (1R-cis)-amino-1,9-dihydro-9-[4-(hydroxymethyl)-2-cyclopenten-1-yl]-6H-pur in-6-one, an antiviral agent, and certain intermediates.

Abstract: Antiviral and antitumor compositions are disclosed comprising a mixture of AZT, ribavirin, d4T or CS-87 with a compound of general formula: ##STR1## wherein Z is H, OH or NH.sub.2, Y is CH, and X is selected from the group consisting of H, N(R).sub.2, SR, OR or halogen, wherein R is H, lower(C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically-acceptable derivatives thereof.

Abstract: Antiviral and antitumor compounds are disclosed of general formula: ##STR1## wherein Z is H, OR' or NH.sub.2, wherein R' is H, (C.sub.1 -C.sub.4)-alkyl, aryl, CHO, (C.sub.1 -C.sub.16)alkanoyl or O.dbd.P(OH).sub.2, Y is CH or N, and X is selected from the group consisting of H, N(R.sub.2), SR, OR' or halogen, wherein R is H, lower-(C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically-acceptable salts thereof.

Abstract: Antiviral and antitumor compounds are disclosed of general formula: ##STR1## wherein Z is H, OR' or NH.sub.2, wherein R' is H, (C.sub.1 -C.sub.4)alkyl, aryl, CHO, (C.sub.1 -C.sub.16)alkanoyl or O.dbd.P(OH).sub.2, Y is CH or N, and X is selected from the group consisting of H, N(R.sub.2), SR, OR' or halogen, wherein R is H, lower(C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically-acceptable salts thereof.

Abstract: Antiviral and antitumor compounds are disclosed of general formula: ##STR1## wherein Z is H, OH or NH.sub.2, Y is CH or N, the bond indicated by C.sub.1 '--C.sub.2 ' is absent or, in combination with the C.sub.1 '--C.sub.2 ' bond is the unit CH.dbd.CH, and X is selected from the group consisting of H, N(R.sub.2), SR, OR or halogen, wherein R is H, lower (C.sub.1 -C.sub.4)alkyl, aryl or mixtures thereof, and the pharmaceutically acceptable salts thereof.

Abstract: Biologically-active (6-amino) purine nucleosides of the formula: ##STR1## are disclosed wherein X is CH or N, and R is selected from the group consisting of N(Y)(Z), SY, OY and halogen, wherein Y and Z are H, lower(alkyl), phenyl or mixtures thereof; and the pharmaceutically-acceptable salts thereof. The compounds exhibit antiviral and antitumor activity.

Abstract: Antiviral (3-ethoxypropionate) esters of (+)-cyclaradine having the formula: ##STR1## In the monoester Ry and Rz are hydrogen. In the diester Ry is the 3-ethoxypropionyl group and Rz is hydrogen. In the triester, Ry and Rz are each 3-ethoxypropionyl groups.

Abstract: The preparation of 9-[.alpha.-(2.alpha.,3.beta.-dihydroxy-4.alpha.-(hydroxymethyl) cyclopentyl)]-6-substituted purines: ##STR1## and their derivatives wherein R is amino, mercapto, methylmercapto, hydroxy, halogen, or substituted amino: ##STR2## wherein R' and R" may be the same or different and are hydrogen, methyl, ethyl, propyl or phenyl. The compounds exhibit anti-viral and antitumor activity and are resistant to adenosine deaminase. Acid salts and esters of the purine nucleosides have also been prepared.

Abstract: Antiviral alkoxyalkanoate esters of cyclaradine having the formula: ##STR1## In the monoester Rx is an alkoxyalkanoyl group and Ry and Rz are hydrogen. In the diester Rx and Ry are alkoxyalkanoyl groups and Rz is hydrogen. In the triester Rx, Ry and Rz are alkoxyalkanoyl groups.

Abstract: Alkoxyalkanoate esters of vidarabine of the formula ##STR1## wherein R.sub.x, R.sub.y and R.sub.z are ##STR2## or hydrogen and wherein R.sub.1 is lower alkyl and R.sub.2 is lower alkylene, which compounds are useful in treating susceptible viral infections, are disclosed.

Abstract: The preparation of (.+-.)-9-[.alpha.-(2.alpha.,3.beta.-dihydroxy-4.alpha.-(hydroxymethyl)cycl opentyl)]-6-substituted purines: ##STR1## and (.+-.)-3-[.alpha.-(2.alpha.,3.beta.-dihydroxy-4.alpha.-(hydroxymethyl)cycl opentyl)]-7-substituted-v-triazolo[4,5d]pyrimidines: ##STR2## and their derivatives wherein R is amino, mercapto, methylmercapto, hydroxy, halogen, or substituted amino: ##STR3## wherein R' and R" may be the same or different and are of hydrogen, methyl, ethyl, propyl or phenyl. The preparation of the single intermediate from which either of these series of compounds may be synthesized is also disclosed. The compounds exhibit antiviral and antitumor activity. Acid salts and esters of the purine nucleosides have also been prepared.

Abstract: The preparation of (+)-9-[.alpha.-(2.alpha.,3.beta.-dihydroxy-4.alpha.-(hydroxymethyl)cyclope ntyl)]-6-substituted purines: ##STR1## and (+)-3-[.alpha.-(2.alpha.,3.beta.-dihydroxy-4.alpha.-(hydroxymethyl)cyclope ntyl)]7-substituted-v-triazolo[4,5d]pyrimidines: ##STR2## and their derivatives wherein R is amino, mercapto, methylmercapto, hydroxy, halogen, or substituted amino: ##STR3## wherein R' and R" may be the same or different and are of hydrogen, methyl, ethyl, propyl or phenyl. The preparation of the single intermediate from which either of these series of compounds may be synthesized is also disclosed. The compounds exhibit antiviral and antitumor activity.

Abstract: The preparation of (.+-.)-9-[.alpha.-(2.alpha.,3.beta.-dihydroxy-4.alpha.-(hydroxymethyl) cyclopentyl)]-6-substituted purines: ##STR1## and (.+-.)-3-[.alpha.-(2.alpha., 3.beta.-dihydroxy-4.alpha.-(hydroxymethyl)cyclopentyl)]-7-substituted-v-tr iazolo[4,5d]pyrimidines: ##STR2## and their derivatives wherein R is amino, mercapto, methylmercapto, hydroxy, halogen, or substituted amino: ##STR3## wherein R' and R" may be the same or different and are of hydrogen, methyl, ethyl, propyl or phenyl. The preparation of the single intermediate from which either of these series of compounds may be synthesized is also disclosed. The compounds exhibit antiviral and antitumor activity.